Highlights & Basics
- Metastatic breast cancer (MBC) demonstrates great heterogeneity in both presentation and prognosis.
- The diagnostic approach for MBC involves identification of risk factors, a full clinical history and physical exam, laboratory investigations, imaging studies, and assessment of tumor biomarker status (where feasible).
- Potential goals of therapy are to maximize progression-free and overall survival, reduce tumor-related symptoms, enhance/maintain performance status, preserve or improve quality of life, and minimize toxicity.
- Biomarkers may be used to guide therapy.
- Systemic therapy (i.e., hormone therapy, chemotherapy, immunotherapy, targeted therapy) is the standard approach for managing MBC.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Citations
Gennari A, André F, Barrios CH, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021 Dec;32(12):1475-95.[Abstract][Full Text]
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer [internet publication].[Full Text]
Rugo HS, Rumble B, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016 Sep 1;34(25):3069-103.[Abstract][Full Text]
Giordano SH, Franzoi MAB, Temin S, et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J Clin Oncol. 2022 Aug 10;40(23):2612-35.[Abstract][Full Text]
Van Poznak C, Somerfield MR, Barlow WE, et al. Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused guideline update. J Clin Oncol. 2017 Dec 10;35(35):3978-86.[Abstract][Full Text]
1. Edge SB, Byrd DR, Brookland RK, et al (eds). AJCC cancer staging manual. 8th ed. New York, NY: Springer; 2017.
2. Leone BA, Romero A, Rabinovich MG, et al. Stage IV breast cancer: clinical course and survival of patients with osseous versus extraosseous metastases at initial diagnosis: the GOCS (Grupo Oncologico Cooperativo del Sur) experience. Am J Clin Oncol. 1988 Dec;11(6):618-22.[Abstract]
3. Mayer EL, Burstein HJ. Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am. 2007 Apr;21(2):257-72.[Abstract]
4. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209-49.[Abstract][Full Text]
5. Gallicchio L, Devasia TP, Tonorezos E, et al. Estimation of the number of individuals living with metastatic cancer in the United States. J Natl Cancer Inst. 2022 Nov 14;114(11):1476-83.[Abstract][Full Text]
6. Gogate A, Wheeler SB, Reeder-Hayes KE, et al. Projecting the prevalence and costs of metastatic breast cancer from 2015 through 2030. JNCI Cancer Spectr. 2021 Jul 13;5(4):pkab063.[Abstract][Full Text]
7. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49.[Abstract][Full Text]
8. National Cancer Institute. Cancer stat facts: female breast cancer [internet publication].[Full Text]
9. Santen RJ. Risk of breast cancer with progestins: critical assessment of current data. Steroids. 2003 Nov;68(10-13):953-64.[Abstract]
10. Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015 Jul;26(7):1291-9.[Abstract][Full Text]
11. Gray JM, Rasanayagam S, Engel C, et al. State of the evidence 2017: an update on the connection between breast cancer and the environment. Environ Health. 2017 Sep 2;16(1):94.[Abstract][Full Text]
12. Gray J, Evans N, Taylor B, et al. State of the evidence: the connection between breast cancer and the environment. Int J Occup Environ Health. 2009 Jan-Mar;15(1):43-78.[Abstract]
13. Riggio AI, Varley KE, Welm AL. The lingering mysteries of metastatic recurrence in breast cancer. Br J Cancer. 2021 Jan;124(1):13-26.[Abstract][Full Text]
14. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010 Jul 10;28(20):3271-7.[Abstract][Full Text]
15. Wang R, Zhu Y, Liu X, et al. The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer. 2019 Nov 12;19(1):1091.[Abstract][Full Text]
16. Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan;73(1):17-48.[Abstract][Full Text]
17. Jin X, Mu P. Targeting breast cancer metastasis. Breast Cancer (Auckl). 2015;9(suppl 1):23-34.[Abstract][Full Text]
18. American Society of Clinical Oncology. Breast cancer - metastatic: statistics. Jan 2022 [internet publication].[Full Text]
19. Eisen A, Irwin E. Review: breast cancer is associated with a family history of the disease in first degree relatives. Evid Based Nurs. 2002 Jul;5(3):89.[Abstract][Full Text]
20. Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med. 2010 May;12(5):245-59.[Abstract][Full Text]
21. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast, ovarian, and pancreatic [internet publication].[Full Text]
22. US Preventive Services Task Force, Owens DK, Davidson KW, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force recommendation statement. JAMA. 2019 Aug 20;322(7):652-65.[Abstract][Full Text]
23. Manahan ER, Kuerer HM, Sebastian M, et al. Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol. 2019 Oct;26(10):3025-31.[Abstract][Full Text]
24. Bedrosian I, Somerfield MR, Achatz MI, et al. Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline. J Clin Oncol. 2024 Feb 10;42(5):584-604.[Abstract][Full Text]
25. Pouptsis A, Swafe L, Patwardhan M, et al. Surgical and systemic treatment of hereditary breast cancer: a mini-review with a focus on BRCA1 and BRCA2 mutations. Front Oncol. 2020 Oct 20;10:553080.[Abstract][Full Text]
26. Gennari A, André F, Barrios CH, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021 Dec;32(12):1475-95.[Abstract][Full Text]
27. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer [internet publication].[Full Text]
28. Rosa Mendoza ES, Moreno E, Caguioa PB. Predictors of early distant metastasis in women with breast cancer. J Cancer Res Clin Oncol. 2013 Apr;139(4):645-52.[Abstract][Full Text]
29. Yao Y, Chu Y, Xu B, et al. Risk factors for distant metastasis of patients with primary triple-negative breast cancer. Biosci Rep. 2019 Jun 28;39(6):BSR20190288.[Abstract][Full Text]
30. Amin MB, Edge S, Greene F, et al (eds). American Joint Committee on Cancer (AJCC) cancer staging manual. 8th ed (3rd printing). Chicago: Springer International Publishing; 2018.
31. Purushotham A, Shamil E, Cariati M, et al. Age at diagnosis and distant metastasis in breast cancer--a surprising inverse relationship. Eur J Cancer. 2014 Jul;50(10):1697-705.[Abstract]
32. Kuhn E, Gambini D, Despini L, et al. Updates on lymphovascular invasion in breast cancer. Biomedicines. 2023 Mar 21;11(3):968.[Abstract][Full Text]
33. Piccart M, van 't Veer LJ, Poncet C, et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 2021 Apr;22(4):476-88.[Abstract]
34. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018 Jul 12;379(2):111-21.[Abstract][Full Text]
35. Lænkholm AV, Jensen MB, Eriksen JO, et al. PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive Danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for hormone receptor-positive early breast cancer. J Clin Oncol. 2018 Mar 10;36(8):735-40.[Abstract][Full Text]
36. Sheehan M, Heald B, Yanda C, et al. Investigating the link between Lynch syndrome and breast cancer. Eur J Breast Health. 2020 Apr;16(2):106-9.[Abstract][Full Text]
37. Kleiblova P, Stolarova L, Krizova K, et al. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer. Int J Cancer. 2019 Oct 1;145(7):1782-97.[Abstract][Full Text]
38. Breast Cancer Association Consortium, Dorling L, Carvalho S, et al. Breast cancer risk genes - association analysis in more than 113,000 women. N Engl J Med. 2021 Feb 4;384(5):428-39.[Abstract][Full Text]
39. Moslemi M, Moradi Y, Dehghanbanadaki H, et al. The association between ATM variants and risk of breast cancer: a systematic review and meta-analysis. BMC Cancer. 2021 Jan 5;21(1):27.[Abstract][Full Text]
40. Carlson RW, Brown E, Burstein HJ, et al. NCCN task force report: adjuvant therapy for breast cancer. J Natl Compr Canc Netw. 2006 Mar;4(suppl 1):S1-26.[Abstract]
41. Smid M, Wang Y, Klijn JG, et al. Genes associated with breast cancer metastatic to bone. J Clin Oncol. 2006;24:2261-2267.[Abstract][Full Text]
42. Landemaine T, Jackson A, Bellahcène A, et al. A six-gene signature predicting breast cancer lung metastasis. Cancer Res. 2008 Aug 1;68(15):6092-9.[Abstract][Full Text]
43. Savci-Heijink CD, Halfwerk H, Koster J, et al. A novel gene expression signature for bone metastasis in breast carcinomas. Breast Cancer Res Treat. 2016 Apr;156(2):249-59.[Abstract][Full Text]
44. Brasó-Maristany F, Paré L, Chic N, et al. Gene expression profiles of breast cancer metastasis according to organ site. Mol Oncol. 2022 Jan;16(1):69-87.[Abstract][Full Text]
45. Irvin W Jr, Muss HB, Mayer DK. Symptom management in metastatic breast cancer. Oncologist. 2011;16(9):1203-14.[Abstract][Full Text]
46. Al-Khalili R, Alzeer A, Nguyen GK, et al. Palpable lumps after mastectomy: radiologic-pathologic review of benign and malignant masses. Radiographics. 2021 Jul-Aug;41(4):967-89.[Abstract][Full Text]
47. Gurkan G, Sarikaya I, Sarikaya A. Semiquantitative assessment of osteoblastic, osteolytic, and mixed lytic-sclerotic bone lesions on fluorodeoxyglucose positron emission tomography/computed tomography and bone scintigraphy. World J Nucl Med. 2019 Apr-Jun;18(2):132-6.[Abstract][Full Text]
48. Quattrocchi CC, Piciucchi S, Sammarra M, et al. Bone metastases in breast cancer: higher prevalence of osteosclerotic lesions. Radiol Med (Torino). 2007 Oct;112(7):1049-59.[Abstract]
49. Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017 Mar 10;35(8):893-911.[Abstract][Full Text]
50. Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol. 2012 Oct;23 Suppl 7:vii155-66.[Abstract][Full Text]
51. Stone JR, Kanneganti R, Abbasi M, et al. Monitoring for chemotherapy-related cardiotoxicity in the form of left ventricular systolic dysfunction: a review of current recommendations. JCO Oncol Pract. 2021 May;17(5):228-36.[Abstract][Full Text]
52. Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update. J Clin Oncol. 2023 Aug 1;41(22):3867-72.[Abstract][Full Text]
53. Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 2018 May 30;36(20):2105-22.[Abstract][Full Text]
54. Rossi S, Basso M, Strippoli A, et al. Hormone receptor status and HER2 expression in primary breast cancer compared with synchronous axillary metastases or recurrent metastatic disease. Clin Breast Cancer. 2015;15:307-312.[Abstract]
55. Henry NL, Somerfield MR, Dayao Z, et al. Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update. J Clin Oncol. 2022 Sep 20;40(27):3205-21.[Abstract][Full Text]
56. Burstein HJ, DeMichele A, Somerfield MR, et al. Testing for ESR1 mutations to guide therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2023 Jun 20;41(18):3423-25.[Abstract][Full Text]
57. Cristo Santos J, Henriques Abreu M, Seoane Santos M, et al. Bone metastases detection in patients with breast cancer: does bone scintigraphy add information to PET/CT? Oncologist. 2023 Aug 3;28(8):e600-5.[Abstract][Full Text]
58. Cahan WG, Woodward HQ, Higinbotham NL, et al. Sarcoma arising in irradiated bone: report of eleven cases. 1948. Cancer. 1998 Jan 1;82(1):8-34.[Abstract][Full Text]
59. Cufer T. Reducing the risk of late recurrence in hormone-responsive breast cancer. Ann Oncol. 2007 Sep;18 Suppl 8:viii18-25.[Abstract]
60. Omuro AM, Leite CC, Mokhtari K, et al. Pitfalls in the diagnosis of brain tumours. Lancet Neurol. 2006 Nov;5(11):937-48.[Abstract]
61. American College of Radiology. ACR practice parameter for the performance of contrast enhanced magnetic resonance imaging (MRI) of the breast. 2023 [internet pubication].[Full Text]
62. American College of Radiology. ACR appropriateness criteria: female breast cancer screening. 2023 [internet publication].[Full Text]
63. Monticciolo DL, Newell MS, Moy L, et al. Breast cancer screening for women at higher-than-average risk: updated recommendations from the ACR. J Am Coll Radiol. 2023 Sep;20(9):902-14.[Abstract][Full Text]
64. Expert Panel on Breast Imaging, Mehta TS, Lourenco AP, et al. ACR appropriateness criteria® imaging after breast surgery. J Am Coll Radiol. 2022 Nov;19(11s):S341-356.[Abstract][Full Text]
65. American College of Radiology. ACR appropriateness criteria: palpable breast masses. 2022 [internet publication].[Full Text]
66. Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020 Apr 20;38(12):1346-66.[Abstract][Full Text]
67. Monticciolo DL, Newell MS, Hendrick RE, et al. Breast cancer screening for average-risk women: recommendations from the ACR Commission on Breast Imaging. J Am Coll Radiol. 2017 Sep;14(9):1137-43.[Abstract]
68. US Preventive Services Task Force. Screening for breast cancer: US Preventive Services Task Force recommendation statement. 2016 [internet publication].[Full Text]
69. National Institute for Health and Care Excellence. Advanced breast cancer: diagnosis and treatment. Aug 2017 [internet publication].[Full Text]
70. Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020 Dec;31(12):1623-49.[Abstract][Full Text]
71. West HJ, Jin JO. JAMA Oncology Patient Page. Performance status in patients with cancer. JAMA Oncol. 2015 Oct;1(7):998.[Abstract]
72. British Geriatrics Society. Comprehensive Geriatric Assessment (CGA) and why it is done? February 2016. http://www.bgs.org.uk/ (last accessed 17 May 2017).[Full Text]
73. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29:3457-3465.[Abstract][Full Text]
74. Hoppe S, Rainfray M, Fonck M, et al. Functional decline in older patients with cancer receiving first-line chemotherapy. J Clin Oncol. 2013;31:3877-3882.[Abstract][Full Text]
75. Soubeyran P, Fonck M, Blanc-Bisson C, et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol. 2012;30:1829-1834.[Abstract][Full Text]
76. Gerber B, Freund M, Reimer T. Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. Dtsch Arztebl Int. 2010 Feb;107(6):85-91.[Abstract][Full Text]
77. Arpino G, Milano M, De Placido S. Features of aggressive breast cancer. Breast. 2015 Oct;24(5):594-600.[Abstract][Full Text]
78. Rugo HS, Rumble B, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016 Sep 1;34(25):3069-103.[Abstract][Full Text]
79. Burstein HJ, Somerfield MR, Barton DL, et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. J Clin Oncol. 2021 Dec 10;39(35):3959-77.[Abstract][Full Text]
80. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan;16(1):25-35.[Abstract]
81. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016 Nov 17;375(20):1925-36.[Abstract][Full Text]
82. Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018 Jul 1;29(7):1541-47.[Abstract][Full Text]
83. Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017 Nov 10;35(32):3638-46.[Abstract][Full Text]
84. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022 Mar 10;386(10):942-50.[Abstract][Full Text]
85. Olson SR, DeLoughery TG, Shatzel JJ. Cyclin-dependent kinase inhibitor-associated thromboembolism. JAMA Oncol. 2019 Feb 1;5(2):141-42.[Abstract]
86. McAndrew NP, Finn RS. Clinical review on the management of hormone receptor-positive metastatic breast cancer. JCO Oncol Pract. 2022 May;18(5):319-27.[Abstract][Full Text]
87. US Food & Drug Administration. FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer. 13 Sep 2019 [internet publication].[Full Text]
88. Martin JM, Handorf EA, Montero AJ, et al. Systemic therapies following progression on first-line CDK4/6-inhibitor treatment: analysis of real-world data. Oncologist. 2022 Jun 8;27(6):441-6.[Abstract][Full Text]
89. Ashai N, Swain SM. Post-CDK 4/6 inhibitor therapy: current agents and novel targets. Cancers (Basel). 2023 Mar 20;15(6):1855.[Abstract][Full Text]
90. Kalinsky K, Accordino MK, Chiuzan C, et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN Trial. J Clin Oncol. 2023 Aug 20;41(24):4004-13.[Abstract]
91. Albanell J, Pérez-García JM, Gil-Gil M, et al. Palbociclib rechallenge for hormone receptor-positive/HER-negative advanced breast cancer: findings from the phase II BioPER trial. Clin Cancer Res. 2023 Jan 4;29(1):67-80.[Abstract][Full Text]
92. Mayer EL, Ren Y, Wagle N, et al. Palbociclib after CDK4/6i and endocrine therapy (PACE): a randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2-metastatic breast cancer. Cancer Res. 2023;83 (supplement 5):GS3-06.
93. Robertson JF, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016 Dec 17;388(10063):2997-3005.[Abstract]
94. Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018 Aug 20;36(24):2465-72.[Abstract][Full Text]
95. Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020 Feb 6;382(6):514-24.[Abstract][Full Text]
96. Slamon DJ, Neven P, Chia S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 2021 Aug;32(8):1015-24.[Abstract][Full Text]
97. Neven P, Fasching PA, Chia S, et al. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Res. 2023 Aug 31;25(1):103.[Abstract][Full Text]
98. Carlini P, Bria E, Giannarelli D, et al. Aromatase inhibitors in post-menopausal metastatic breast carcinoma. Expert opinion on investigational drugs. Expert Opin Investig Drugs. 2007 Jul;16(7):1023-36.[Abstract]
99. Riemsma R, Forbes CA, Kessels A, et al. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Res Treat. 2010 Aug;123(1):9-24.[Abstract]
100. Gibson L, Lawrence D, Dawson C, et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD003370.[Abstract][Full Text]
101. Moy B, Rumble RB, Come SE, et al. Chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor-negative: ASCO guideline update. J Clin Oncol. 2021 Dec 10;39(35):3938-58.[Abstract][Full Text]
102. Moy B, Rumble RB, Carey LA, et al. Chemotherapy and targeted therapy for human epidermal growth factor receptor 2-negative metastatic breast cancer that Is either endocrine-pretreated or hormone receptor-negative: ASCO guideline rapid recommendation update. J Clin Oncol. 2022 Sep 10;40(26):3088-90.[Abstract][Full Text]
103. Moy B, Rumble RB, Carey LA, et al. Chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor-negative metastatic breast cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2023 Feb 20;41(6):1318-20.[Abstract][Full Text]
104. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012 Feb 9;366(6):520-9.[Abstract][Full Text]
105. Pritchard KI, Burris HA 3rd, Ito Y, et al. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer. 2013 Dec;13(6):421-32.e8.[Abstract][Full Text]
106. Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013 Oct 25;30(10):870-84.[Abstract][Full Text]
107. Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015 Jul 16;373(3):209-19.[Abstract][Full Text]
108. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016 Apr;17(4):425-39.[Abstract]
109. Valachis A, Mauri D, Polyzos NP, et al. Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol. 2010 Mar;73(3):220-7.[Abstract]
110. Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017 Sep 1;35(25):2875-84.[Abstract][Full Text]
111. Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018 Nov 15;379(20):1926-36.[Abstract][Full Text]
112. Sledge GW Jr, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020 Jan 1;6(1):116-24.[Abstract][Full Text]
113. André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019 May 16;380(20):1929-40.[Abstract]
114. André F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021 Feb;32(2):208-17.[Abstract][Full Text]
115. Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023 Jun 1;388(22):2058-70.[Abstract][Full Text]
116. Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022 Oct 1;40(28):3246-56.[Abstract][Full Text]
117. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol. 2000 Apr;18(7):1399-411.[Abstract]
118. Stebbing J, Ngan S. Breast cancer (metastatic). BMJ Clin Evid. 2010 Sep 8;2010:0811.[Abstract][Full Text]
119. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 15;379(8):753-63.[Abstract][Full Text]
120. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Jun 4;377(6):523-33.[Abstract][Full Text]
121. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022 Jul 7;387(1):9-20.[Abstract][Full Text]
122. Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 Oct 21;402(10411):1423-33.[Abstract][Full Text]
123. Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, A phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. Clin Cancer Res. 2017 Sep 1;23(17):5218-24.[Abstract][Full Text]
124. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-82.[Abstract][Full Text]
125. Demetri GD, De Braud F, Drilon A, et al. Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res. 2022 Apr 1;28(7):1302-12.[Abstract][Full Text]
126. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018 Feb 22;378(8):731-9.[Abstract][Full Text]
127. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015 Jun 25;372(26):2509-20.[Abstract][Full Text]
128. Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020 Oct;21(10):1353-65.[Abstract]
129. André T, Berton D, Curigliano G, et al. Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial. JAMA Netw Open. 2023 Nov 1;6(11):e2341165.[Abstract][Full Text]
130. Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 Oct;23(10):1261-73.[Abstract]
131. Taylor CW, Green S, Dalton WS, et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol. 1998 Mar;16(3):994-9.[Abstract]
132. Boccardo F, Rubagotti A, Perotta A, et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol. 1994 Apr;5(4):337-42.[Abstract]
133. Crump M, Sawka CA, DeBoer G, et al. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first-line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat. 1997 Jul;44(3):201-10.[Abstract]
134. Sawka CA, Pritchard KI, Shelley W, et al. A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada clinical trials group trial MA1. Breast Cancer Res Treat. 1997 Jul;44(3):211-5.[Abstract]
135. Giordano SH, Franzoi MAB, Temin S, et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J Clin Oncol. 2022 Aug 10;40(23):2612-35.[Abstract][Full Text]
136. Baselga J, Cortés J, Kim SB, et al; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012 Jan 12;366(2):109-19.[Abstract][Full Text]
137. Swain SM, Baselga J, Kim SB, et al; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015 Feb 19;372(8):724-34.[Abstract][Full Text]
138. Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020 Apr;21(4):519-30.[Abstract]
139. Drucker AM, Wu S, Dang CT, et al. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast Cancer Res Treat. 2012 Sep;135(2):347-54.[Abstract]
140. Tan AR, Im SA, Mattar A, et al. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2021 Jan;22(1):85-97.[Abstract]
141. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009 Nov 20;27(33):5529-37.[Abstract][Full Text]
142. Cortés J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022 Mar 24;386(12):1143-54.[Abstract]
143. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023 Jan 14;401(10371):105-17.[Abstract][Full Text]
144. Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020 Feb 13;382(7):610-21.[Abstract][Full Text]
145. Ramakrishna N, Anders CK, Lin NU, et al. Management of advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO guideline update. J Clin Oncol. 2022 Aug 10;40(23):2636-55.[Abstract][Full Text]
146. Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020 Feb 13;382(7):597-609.[Abstract][Full Text]
147. Lin NU, Murthy RK, Abramson V, et al. Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial. JAMA Oncol. 2022 Dec 1;e225610. [Epub ahead of print].[Abstract][Full Text]
148. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006 Dec 28;355(26):2733-43.[Abstract][Full Text]
149. Rugo HS, Im SA, Cardoso F, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021 Apr 1;7(4):573-84.[Abstract][Full Text]
150. Saura C, Oliveira M, Feng YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020 Sep 20;38(27):3138-49.[Abstract][Full Text]
151. von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol. 2009 Apr 20;27(12):1999-2006.[Abstract][Full Text]
152. Gori S, Montemurro F, Spazzapan S, et al. Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Ann Oncol. 2012 Jun;23(6):1436-41.[Abstract][Full Text]
153. Balduzzi S, Mantarro S, Guarneri V, et al. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2014 Jun 12;(6):CD006242.[Abstract][Full Text]
154. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996 Mar;14(3):737-44.[Abstract]
155. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010 Mar 1;28(7):1124-30.[Abstract][Full Text]
156. Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012 Jul 20;30(21):2585-92.[Abstract][Full Text]
157. Emens LA, Adams S, Cimino-Mathews A, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer. 2021 Aug;9(8):e002597.[Abstract][Full Text]
158. Litton JK, Hurvitz SA, Mina LA, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 Nov;31(11):1526-35.[Abstract][Full Text]
159. Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-66.[Abstract][Full Text]
160. Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018 May;24(5):628-37.[Abstract][Full Text]
161. Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020 Dec 5;396(10265):1817-28.[Abstract]
162. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021 Apr 22;384(16):1529-41.[Abstract][Full Text]
163. Ghersi D, Willson ML, Chan MM, et al. Taxane-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2015 Jun 10;(6):CD003366.[Abstract][Full Text]
164. O'Shaughnessy J, Gradishar WJ, Bhar P, et al. Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis. Breast Cancer Res Treat. 2013 Apr;138(3):829-37.[Abstract][Full Text]
165. O'Brien ME, Wigler N, Inbar M, et al; CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004 Mar;15(3):440-9.[Abstract]
166. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007 Nov 20;25(33):5210-7.[Abstract][Full Text]
167. Kardinal C, Cole J. Breast cancer. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2008.
168. Van Poznak C, Somerfield MR, Barlow WE, et al. Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused guideline update. J Clin Oncol. 2017 Dec 10;35(35):3978-86.[Abstract][Full Text]
169. Lutz S, Balboni T, Jones J, et al. Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017 Jan - Feb;7(1):4-12.[Abstract][Full Text]
170. Coleman R, Hadji P, Body JJ, et al. Bone health in cancer: ESMO clinical practice guidelines. Ann Oncol. 2020 Dec;31(12):1650-63.[Abstract][Full Text]
171. US Food and Drug Administration. FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab). Nov 2022 [internet publication].[Full Text]
172. Ruiterkamp J, Voogd AC, Bosscha K, et al. Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature. Breast Cancer Res Treat. 2010 Feb;120(1):9-16.[Abstract]
173. Khan SA, Zhao F, Goldstein LJ, et al. Early local therapy for the primary site in de novo stage IV breast cancer: results of a randomized clinical trial (EA2108). J Clin Oncol. 2022 Mar 20;40(9):978-87.[Abstract][Full Text]
174. Yardley DA, Ismail-Khan RR, Melichar B, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013 Jun 10;31(17):2128-35.[Abstract]
175. ClinicalTrials.gov. Ph3 study of exemestane with or without entinostat in chinese patients with hormone receptor-positive, locally advanced or metastatic breast cancer. ClinicalTrials.gov identifier: NCT03538171. Jul 2021 [internet publication].[Full Text]
176. ClinicalTrials.gov. Entinostat in patients with recurrent advanced hormone receptor-positive breast cancer. ClinicalTrials.gov identifier: NCT02115282. Nov 2021 [internet publication].[Full Text]
177. Vogelbaum MA, Brown PD, Messersmith H, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol. 2022 Feb 10;40(5):492-516.[Abstract][Full Text]
178. Rock CL, Thomson CA, Sullivan KR, et al. American Cancer Society nutrition and physical activity guideline for cancer survivors. CA Cancer J Clin. 2022 May;72(3):230-62.[Abstract][Full Text]
179. Ligibel JA, Bohlke K, May AM, et al. Exercise, diet, and weight management during cancer treatment: ASCO guideline. J Clin Oncol. 2022 Aug 1;40(22):2491-507.[Abstract][Full Text]
180. American College of Radiology. ACR appropriateness criteria: plexopathy. 2021 [internet publication].[Full Text]
181. Khatcheressian JL, Hurley P, Bantug E, et al; American Society of Clinical Oncology. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 Mar 1;31(7):961-5.[Abstract][Full Text]
182. Klar N, Rosenzweig M, Diergaarde B, et al. Features associated with long-term survival in patients with metastatic breast cancer. Clin Breast Cancer. 2019 Aug;19(4):304-10.[Abstract]
183. Leone JP, Leone J, Vallejo CT, et al. Factors associated with short- and long-term survival in metastatic HER2+ breast cancer. J Clin Oncol. 2022 40:16_suppl, 1047 [Epub ahead of print].[Full Text]
184. Mariotto AB, Etzioni R, Hurlbert M, et al. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):809-15.[Abstract][Full Text]
185. Valachis A, Carlqvist P, Ma Y, et al. Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study. Br J Cancer. 2022 Sep;127(4):720-5.[Abstract][Full Text]
186. Gomes I, Aguiar P, Miranda A, et al. Overall survival of patients with locoregional and metastatic breast cancer: is the influence of baseline characteristics the same? Anticancer Res. 2019 Sep;39(9):5135-42.[Abstract][Full Text]
187. Zeichner SB, Herna S, Mani A, et al. Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature. Breast Cancer Res Treat. 2015 Oct;153(3):617-24.[Abstract]
188. Layman R, Olson K, Van Poznak C. Bisphosphonates for breast cancer: questions answered, questions remaining. Hematol Oncol Clin North Am. 2007 Apr;21(2):341-67.[Abstract]
189. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004 Aug 19;351(8):781-91.[Abstract][Full Text]
